ClinicalTrials.gg
RecruitingNCT07303270EmoTDIUpdated Apr 1, 2026

Emotional Processes in Adults With Intellectual Developmental Disorder

An interventional study of ACQUISS protocol assessing emotional processing. in Intellectual Developmental Disorder, sponsored by Hôpital le Vinatier. Recruiting at 1 site in France. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Hôpital le Vinatier · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

Emotions play a crucial part in the quality of life, interpersonal relationships and mental health in general. In adults presenting with intellectual developmental disorder (IDD), emotional abilities may be hindered, thus leading to more challenging behaviors. A better understanding of emotional processes of adults with IDD may help improve the efficiency of behavioral interventions and better improve their quality of life.

The primary goal of this study is to better characterize the abilities and weaknesses of adults with IDD concerning their emotional processes, in comparison to a healthy population. The secondary goals are :

  • to determine if these difficulties are underlined by oculomotor and attention (auditory and visual) processes
  • to determine if behavioral difficulties, as reported by the families of adults with IDD, are underlined by specific difficulties in facial emotion recognition, emotion identification in context and/or identification of vocal emotions.
Read the detailed description

The study will be carried out in 3 steps :

Step 1: All participants will undergo tests to evaluate their intellectual abilities, and auditory and visual screening tests.

Step 2 : All participants will undergo neuropsychological tests assessing attentional and oculomotor abilities (1 hour). During this time, the participant's family member will complete the questionnaires assessing behavior.

Step 3 : All participants will undergo the experimental ACQUISS protocol (task 1 : faces; task 2 : faces in context; task 3 : prosody) (1 hour).

Detailed Description:

Step 1 :

During this first step, all participants (both groups), will undergo the Raven Progressive Matrices (John and Raven 2003) to assess their intellectual abilities. They will then undergo an auditory screening test (tonality test) and a visual screening task (the Rossano-Weiss scale and the Palettes de Léa Grattins task).

Step 2 :

During this second step, all participants (both groups) will undergo :

  1. - the tangled lines test (Rey, 1964) : in this task, the participant must follow by gaze entangled lines to determine the beginning and end of each line.
  2. - the NSUCO oculomotor test (Maillet, 2015) : the orthoptist will evaluate the ability of the participant to carry out ocular saccades and movement pursuit.
  3. - the Auditory attention task of the NEPSY-II battery (Korkman et al., 2012)
  4. - 2 cancellation tests from the EVA battery (Chokron, 2010):

    • the TeddyBear Cancellation test
    • the single-letter cancellation test

Step 3:

During this step, all participants from both groups will undergo the ACQUISS protocol.

02

Conditions studied

  • Intellectual Developmental Disorder

Keywords

  • Intellectual Developmental Disorder
  • emotional processing
  • Cognitive assessments
  • Social cognition
03

In context

Intellectual Disability

387 studies on the registry are indexed under Intellectual Disability; 105 are open to participants now.

This study's planned enrollment of 60 is close to the median of 58 across 248 interventional studies indexed under Intellectual Disability.

Browse Intellectual Disability studies →

Lead sponsor

Hôpital le Vinatier is the lead sponsor of 106 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

IDD group :

  • Diagnosis of IDD according to criteria
  • aged between 18 and 3 years
  • French speaking
  • Membership or entitlement to a social security plan
  • , or that of the tutor, to take part in the study
  • presence of a caregiver to complete the questionnaires at V2.

Control group :

  • aged between 18 and 35 years
  • French speaking
  • Membership or entitlement to a social security plan
  • Informed written consent to take part in the study.

Exclusion criteria

Exclusion Criteria:

IDD group :

  • visual or auditory impairments, evaluated at V1
  • non stabilized epilepsy
  • undergoing treatments that can impact brain or psychological functioning
  • major motor disorders
  • breastfeeding or pregnant woman

Control group :

  • neurodevelopmental or psychiatric disorder
  • history of brain trauma (TBI, stroke, etc…) or non-stabilized epilepsy
  • visual or auditory impairments, evaluated at V1
  • non stabilized epilepsy
  • undergoing treatments that can impact brain or psychological functioning
  • major motor disorders
  • breastfeeding or pregnant woman
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    IDD group

    adults with Intellectual Developmental Disorder

    Other: ACQUISS protocol assessing emotional processing.

  • Other
    Control group

    healthy adults

    Other: ACQUISS protocol assessing emotional processing.

Interventions

  • OtherACQUISS protocol assessing emotional processing.

    Task 1: 5 minute facial emotion recognition test to identify isolated facial expressions. 6 drawn faces, without gender bias, without hair, expressing the 6 universal emotions will be presented. The emotions are: happiness, sadness, anger, fear, surprise and disgust. Task 2 : identifying a character's emotion in a social context (20 min). The subject is presented with drawn social contexts, one character is always in orange, and the face is left blank. The subject then has to choose amongst 6 emotions (happiness, sadness, anger, fear, surprise and disgust) which one would correspond the most to the emotion expressed by the character in orange. Task 3 : recognizing vocal emotions (15 min). The subject is presented with dialogues of 3 sentences. The 3 sentences are expressed with a vocal emotion (same emotion for the 3 sentences). The contents of the sentences are neutral At the end of each dialogue, the subject has to show which emotion was expressed.

06

What researchers measure

Primary outcomes

  1. proportion of correct answers on the ACQUISS battery

    proportion of correct answers in each of the 3 tasks

    Time frame: Baseline

Secondary outcomes

  1. Proportion of correct answers on the Entangled lines test

    Time frame: Baseline

  2. Proportion of correct answers on the NSUCO test

    Northeastern State University College of Optometry test.

    Time frame: Baseline

  3. Proportion of correct answers on an auditory attentional task (NEPSY-II)

    Time frame: Baseline

  4. Proportion of correct signs barred on the TeddyBear task

    Time frame: Baseline

  5. Proportion of correct signs barred on the letter task

    Time frame: Baseline

  6. Score on the Agressivity questionnaire

    Score on the Agressivity questionnaire ("Problematic behavior in group settings"), filled in by a caregiver. Minimum score = 6; Maximum score = 30. Higher scores suggest greater agressivity.

    Time frame: Baseline

  7. Score on the Aberrant Behavior Checklist

    Score on the Aberrant Behavior Checklist, filled in by a caregiver. Minimum = 0; Maximum = 174. Higher scores reflect more severe levels of challenging behavior.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Aug 2028, 30 months after the start.

Of 155 non-industry interventional studies with no phase under Intellectual Disability, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 30 months is above that.

Counting every sponsor, half of 158 studies reached it within 19 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Dec 24, 2025
StartActual
Feb 19, 2026
Primary completionEst.
Aug 2028
CompletionEst.
Nov 20, 2028
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07303270
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Feb 19, 2026
Primary completion
Aug 2028 (estimated)
Completion
Nov 20, 2028 (estimated)
Last update
Apr 1, 2026

Study contacts

Marie-Noelle Babinet, PhD
Contact
marie-noelle.babinet@ch-le-vinatier.fr
+33437915380
Méline Devaluez, PhD
Contact
meline.devaluez@ch-le-vinatier.fr
+33437915514

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion